In addition, combination treatment with NHE1 blockade, TMZ, and the anti-PD-1 immune checkpoint therapy prolonged the glioma-bearing mouse median survival in both SB28-GFP and GL26 glioma models. The gene discussed is SLC9A1; the disease is glioma.